BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30075600)

  • 21. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses.
    Van Gorp T; Veldman J; Van Calster B; Cadron I; Leunen K; Amant F; Timmerman D; Vergote I
    Eur J Cancer; 2012 Jul; 48(11):1649-56. PubMed ID: 22226481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases.
    Molina R; Escudero JM; Augé JM; Filella X; Foj L; Torné A; Lejarcegui J; Pahisa J
    Tumour Biol; 2011 Dec; 32(6):1087-95. PubMed ID: 21863264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?
    Kaijser J; Van Gorp T; Smet ME; Van Holsbeke C; Sayasneh A; Epstein E; Bourne T; Vergote I; Van Calster B; Timmerman D
    Ultrasound Obstet Gynecol; 2014 Jan; 43(1):89-97. PubMed ID: 23828371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraoperative laparoscopic sonography for improved preoperative sonographic pathologic characterization of adnexal masses.
    Yang WT; Yuen PM; Ho SS; Leung TN; Metreweli C
    J Ultrasound Med; 1998 Jan; 17(1):53-61. PubMed ID: 9440109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the predictive performance of risk of malignancy indexes 1-4, HE4 and risk of malignancy algorithm in the triage of adnexal masses.
    Hada A; Han LP; Chen Y; Hu QH; Yuan Y; Liu L
    J Ovarian Res; 2020 Apr; 13(1):46. PubMed ID: 32334618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
    Czekierdowski A
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
    Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
    Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of the non-invasive tests for the diagnosis of endometriosis.
    Nisenblat V; Prentice L; Bossuyt PM; Farquhar C; Hull ML; Johnson N
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD012281. PubMed ID: 27405583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
    Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
    Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of CA 125 alone and risk of ovarian malignancy algorithm (ROMA) in patients with adnexal mass: A multicenter study.
    Choi HJ; Lee YY; Sohn I; Kim YM; Kim JW; Kang S; Kim BG
    Curr Probl Cancer; 2020 Apr; 44(2):100508. PubMed ID: 31708114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses.
    Gentry-Maharaj A; Burnell M; Dilley J; Ryan A; Karpinskyj C; Gunu R; Mallett S; Deeks J; Campbell S; Jacobs I; Sundar S; Menon U
    Am J Obstet Gynecol; 2020 Jan; 222(1):56.e1-56.e17. PubMed ID: 31351062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significance of adding progesterone to the Risk of Ovarian Malignancy Algorithm for early stage ovarian cancer detection in patients with a pelvic mass: A single-center case-control study.
    Pitynski K; Sporek A; Lipinska I; Banas T; Ludwin A; Bałajewicz-Nowak M
    Taiwan J Obstet Gynecol; 2015 Dec; 54(6):766-72. PubMed ID: 26701000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective study to evaluate the risk malignancy index and its diagnostic implication in patients with suspected ovarian mass.
    Dora SK; Dandapat AB; Pande B; Hota JP
    J Ovarian Res; 2017 Aug; 10(1):55. PubMed ID: 28806987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison of laparoscopic vs. laparotomy treatment in ovarian teratomas].
    Briones-Landa CH; Ayala-Yáñez R; Leroy-López L; Anaya-Coeto H; Santarosa-Pérez MA; Reyes-Muñoz E
    Ginecol Obstet Mex; 2010 Oct; 78(10):527-32. PubMed ID: 21966769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The management of adnexal masses in premenopausal patients: a ten-year retrospective study at a single center.
    Ozcan HC; Balat O; Ugur MG; Kul S; Bozdag Z; Sucu S; Keklikcioglu I
    Eur J Gynaecol Oncol; 2017; 38(3):372-377. PubMed ID: 29693876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adding cancer antigen 125 screening to gray scale sonography for predicting specific diagnosis of benign adnexal masses in premenopausal women: is it worthwhile?
    Alcázar JL; Guerriero S; Mínguez JÁ; Ajossa S; Paoletti AM; Ruiz-Zambrana A; Jurado M
    J Ultrasound Med; 2011 Oct; 30(10):1381-6. PubMed ID: 21968488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discriminative value of CA-125, HE4, Risk of Malignancy Index II (RMI-II) and Risk of Malignancy Algorithm (ROMA) in the differential diagnosis of pelvic masses: conclusions from a referral Centre in Portugal.
    Melo Â; Veríssimo R; Farinha M; Martins NN; Martins FN
    J Obstet Gynaecol; 2018 Nov; 38(8):1140-1145. PubMed ID: 29884096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic performance of human epididymis protein 4 compared to a combination of biophysical and biochemical markers to differentiate ovarian endometriosis from epithelial ovarian cancer in premenopausal women.
    Nikolova T; Zivadinovic R; Evtimovska N; Klisarovska V; Stanojevic M; Georgievska J; Nikolova N
    J Obstet Gynaecol Res; 2017 Dec; 43(12):1870-1879. PubMed ID: 29027715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
    Lycke M; Kristjansdottir B; Sundfeldt K
    Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transvaginal ultrasound and computed tomography combined with clinical parameters and CA-125 determinations in the differential diagnosis of persistent ovarian cysts in premenopausal women.
    Guerriero S; Mallarini G; Ajossa S; Risalvato A; Satta R; Mais V; Angiolucci M; Melis GB
    Ultrasound Obstet Gynecol; 1997 May; 9(5):339-43. PubMed ID: 9201878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.